These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14677541)

  • 1. 6TG: when less is more than you bargained for.
    Mahadevan U
    Inflamm Bowel Dis; 2003 Nov; 9(6):394-5. PubMed ID: 14677541
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M; Herrlinger K; Schaeffeler E; Stange EF
    Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
    [No Abstract]   [Full Text] [Related]  

  • 3. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine.
    de Jong D; Mulder CJ; van Sorge AA
    Gut; 2001 Dec; 49(6):874. PubMed ID: 11758505
    [No Abstract]   [Full Text] [Related]  

  • 4. What are the rules when treatment with 6-MP/AZA is started?
    Korelitz BI
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S262-3. PubMed ID: 18816727
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
    Griffiths AM
    Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
    de Boer NKH; Peyrin-Biroulet L; Jharap B; Sanderson JD; Meijer B; Atreya I; Barclay ML; Colombel JF; Lopez A; Beaugerie L; Marinaki AM; van Bodegraven AA; Neurath MF
    J Crohns Colitis; 2018 Apr; 12(5):610-620. PubMed ID: 29293971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.
    Louis E; Belaiche J
    Best Pract Res Clin Gastroenterol; 2003 Feb; 17(1):37-46. PubMed ID: 12617881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
    Derijks LJ; Gilissen LP; de Boer NK; Mulder CJ
    J Hepatol; 2006 Apr; 44(4):821-2. PubMed ID: 16487623
    [No Abstract]   [Full Text] [Related]  

  • 9. Monitoring of AZA/6-MP treatment in children with IBD is necessary.
    Dubinsky MC
    Inflamm Bowel Dis; 2003 Nov; 9(6):386-8; discussion 392-3. PubMed ID: 14671488
    [No Abstract]   [Full Text] [Related]  

  • 10. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease.
    Marion JF
    Inflamm Bowel Dis; 1998 May; 4(2):116-7. PubMed ID: 9687219
    [No Abstract]   [Full Text] [Related]  

  • 11. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
    Su CG; Stein RB; Lewis JD; Lichtenstein GR
    Dig Liver Dis; 2000; 32(6):518-31. PubMed ID: 11057928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients.
    de Boer NK; Derijks LJ; Gilissen LP; Hommes DW; Engels LG; de-Boer SY; den Hartog G; Hooymans PM; Mäkelburg AB; Westerveld BD; Naber AH; Mulder CJ; de Jong DJ
    World J Gastroenterol; 2005 Sep; 11(35):5540-4. PubMed ID: 16222751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.
    Gisbert JP; González-Lama Y; Maté J
    Am J Gastroenterol; 2007 Jul; 102(7):1518-27. PubMed ID: 17391318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
    Thomas CW; Lowry PW; Franklin CL; Weaver AL; Myhre GM; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
    Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine.
    Bowen DG; Selby WS
    Dig Dis Sci; 2000 Sep; 45(9):1810-3. PubMed ID: 11052324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists.
    Wallace TM; Veldhuyzen van Zanten SJ
    Can J Gastroenterol; 2001 Jan; 15(1):21-8. PubMed ID: 11173323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azathioprine-induced hypersensitivity hepatitis: tolerance to 6-mercaptopurine.
    Andrejic J; Rojas-Balcazar J; Dennis M; Berkelhammer C
    Inflamm Bowel Dis; 2010 Nov; 16(11):1828-9. PubMed ID: 20196148
    [No Abstract]   [Full Text] [Related]  

  • 20. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.